Prestige Biologics Balance Sheet Health
Financial Health criteria checks 2/6
Prestige Biologics has a total shareholder equity of ₩71.7B and total debt of ₩173.0B, which brings its debt-to-equity ratio to 241.3%. Its total assets and total liabilities are ₩289.4B and ₩217.7B respectively.
Key information
241.3%
Debt to equity ratio
₩172.96b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩29.51b |
| Equity | ₩71.68b |
| Total liabilities | ₩217.73b |
| Total assets | ₩289.41b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: A334970's short term assets (₩55.6B) do not cover its short term liabilities (₩92.3B).
Long Term Liabilities: A334970's short term assets (₩55.6B) do not cover its long term liabilities (₩125.4B).
Debt to Equity History and Analysis
Debt Level: A334970's net debt to equity ratio (200.1%) is considered high.
Reducing Debt: A334970's debt to equity ratio has increased from 103.1% to 241.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A334970 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A334970 is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.